SIG-002 / Eli Lilly - LARVOL DELTA

Shielded Living Therapeutics platform for the treatment of type 1 diabetes (IPITA-IXA-CTRMS 2023) - "We have shown that SIG-002 is efficacious and that Afibromer alginate mitigates the foreign body response. With these encouraging preclinical data, we have laid the foundation for achieving our goal of developing a functional cure for T1D."

Diabetes • Fibrosis • Metabolic Disorders • Type 1 Diabetes Mellitus